Chronic Lymphocytic Leukemia

December 17, 2020 - The FDA has approved rituximab-arrx, a biosimilar to rituximab, for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

December 8, 2020 - The combination of venetoclax and rituximab to retreat patients with relapsed/refractory chronic lymphocytic leukemia demonstrated a sustained time to next treatment benefit according to 5-year follow-up data of the MURANO study in a poster presentation at the 2020 ASH Meeting.

December 8, 2020 - The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

December 7, 2020 — The combination of ublituximab and umbralisib, 2 novel compounds targeting CD20 and PI3Kδ, respectively, has shown synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

William G. Wierda, MD, PhD, discusses results from the CAPTIVATE trial in chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.

December 5, 2020 - Patients with previously untreated chronic lymphocytic leukemia /small lymphocytic lymphoma who received a placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease.

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Emily C. Ayers, MD, hematologist​/oncologist​, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

December 1, 2020 - A rolling submission of a biologics license application to the FDA has been initiated for the CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta and CK1-epsilon inhibitor umbralisib for the treatment of patients with chronic lymphocytic leukemia.

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the role of frontline targeted therapies in chronic lymphocytic leukemia.

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

Emily C. Ayers, MD, discusses recent trials examining the use of venetoclax in patients with chronic lymphocytic leukemia.

Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Alan P. Z. Skarbnik, MD, breaks down factors that should be kept in mind when navigating the complex chronic lymphocytic leukemia armamentarium as it relates to BTK inhibitors.

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Matthew Lunning, DO, discussed other key considerations for choosing treatments, continuous vs fixed-duration therapies, and emerging agents for patients with relapsed/ refractory CLL and SLL.

Emily C. Ayers, MD, discusses unmet needs in chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.